Serdar DURDAĞI, Yeşim YUMAK, Lalehan OKTAY, Ece ERDEMOĞLU, İlayda TOLU, Ayşenur ÖZCAN, Elif ACAR, Şehriban BÜYÜKKILIÇ, Alpsu OLKAN

Binary-QSAR guided virtual screening of FDA approved drugs and compounds in clinical investigation against SARS-CoV-2 main protease

: With the emergence of the new SARS-CoV-2 virus, drug repurposing studies have gained substantial importance. Combined with the efficacy of recent improvements in ligand- and target-based virtual screening approaches, virtual screening has become faster and more productive than ever. In the current study, an FDA library of approved drugs and compounds under clinical investigation were screened for their antiviral activity using the antiviral therapeutic activity binary QSAR model of the MetaCore/MetaDrug platform. Among 6733-compound collection, we found 370 compounds with a normalized therapeutic activity value greater than a cutoff of 0.75. Only these selected compounds were used for molecular docking studies against the SARS-CoV-2 main protease $(M^{pro}).$ After initial short (10 ns) molecular dynamics (MD) simulations with the top-50 docking scored compounds and following molecular mechanics generalized born surface area (MM/GBSA) calculations, top-10 compounds were subjected to longer (100 ns) MD simulations and end-point MM/GBSA estimations. Our virtual screening protocol yielded Cefuroxime pivoxetil, an ester prodrug of second-generation cephalosporin antibiotic Cefuroxime, as being a considerable molecule for drug repurposing against the $SARS-CoV-2 M^{pro}.$

PDF

___

Ahmed MZ, Zia Q, Haque A, Alqahtani AS, Almarfadi OM et al. (2021). Aminoglycosides as potential inhibitors of SARSCoV-2 main protease: an in silico drug repurposing study on FDA-approved antiviral and anti-infection agents. Journal of Infection and Public Health 14 (5): 611-619. doi: 10.1016/j. jiph.2021.01.016
Akhoon BA, Tiwari H, Nargotra A (2019). In silico drug design methods for drug repurposing. In: Roy K (editor). In Silico Drug Design. Cambridge, MA, USA: Academic Press, pp. 47- 84.
Behnam MAM (2021). Protein structural heterogeneity: a hypothesis for the basis of proteolytic recognition by the main protease of SARS-CoV and SARS-CoV-2. Biochimie 182: 177-184. doi: 10.1016/j.biochi.2021.01.010
Chen Y, Liu Q, Guo D (2020). Emerging coronaviruses: genome structure, replication, and pathogenesis. Journal of Medical Virology 92 (4): 418-423. doi: 10.1002/jmv.25681
Dalerba P, Levin B, Thompson JL (2020). A trial of lopinavir-ritonavir in Covid-19. The New England Journal of Medicine 382 (21).
Dogan B, Durdagi S (2020). Drug re‐positioning studies for novel HIV‐1 inhibitors using binary QSAR models and multi‐target‐ driven in silico studies. Molecular Informatics 40 (2000012): 1-15. doi: 10.1002/minf.202000012
Dong L, Tian J, He S, Zhu C, Wang J et al. (2020). Possible vertical transmission of SARS-CoV-2 from an infected mother to her newborn. JAMA 323 (18): 1846-1848. doi: 10.1001/ jama.2020.4621
Durdağı S (2020). Virtual drug repurposing study against SARSCoV-2 TMPRSS2 target. Turkish Journal of Biology 44: 185- 191.
Durdagi S, Aksoydan B, Dogan B, Sahin K, Shahraki A (2020). Screening of clinically approved and investigation drugs as potential inhibitors of COVID-19 main protease: a virtual drug repurposing study. ChemRxiv 2020. doi: 10.26434/ chemrxiv.12032712.v1
Erben Y, Franco-Mesa C, Gloviczki P, Stone W, Quinones-Hinojoas A et al. (2021). Deep vein thrombosis and pulmonary embolism among hospitalized coronavirus disease 2019–positive patients predicted for higher mortality and prolonged intensive care unit and hospital stays in a multisite healthcare system. Journal of Vascular Surgery: Venous and Lymphatic Disorders. doi: 10.1016/j.jvsv.2021.03.009
Ghosh AK, Brindisi M, Shahabi D, Chapman ME, Mesecar AD (2020). Drug development and medicinal chemistry efforts toward SARS‐coronavirus and Covid‐19 therapeutics. ChemMedChem 15 (11): 907-932. doi: 10.1002/ cmdc.202000223
Guedes IA, Costa LSC, Dos Santos KB, Karl ALM, Rocha GK et al. (2021). Drug design and repurposing with DockThor-VS web server focusing on SARS-CoV-2 therapeutic targets and their non-synonym variants. Scientific Reports 11 (1): 5543. doi: 10.1038/s41598-021-84700-0
Han YJ, Lee KH, Yoon S, Nam SW, Ryu S et al. (2021). Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of in vitro, in vivo, and clinical trials. Theranostics 11 (3): 1207-1231. doi: 10.7150/ thno.48342
Haston JC, Hwang J, Tan KR (2019). Guidance for using tafenoquine for prevention and antirelapse therapy for malaria — United States, 2019. Morbidity and Mortality Weekly Report 68 (46): 1062-1068. doi: 10.15585/mmwr.mm6846a4
Hou T, Wang J, Li Y, Wang W (2011). Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. Journal of Chemical Information and Modeling 51: 69-82.
Horby PW, Mafham M, Bell JL, Linsell L, Staplin N et al. (2020). Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, openlabel, platform trial. The Lancet 396 (10259): 1345-1352.
Kanan D, Kanan T, Dogan B, Orhan MD, Avsar T (2021). An integrated in silico approach and in vitro study for the discovery of small‐molecule USP7 inhibitors as potential cancer therapies. ChemMedChem 16 (3): 555-567. doi: 10.1002/cmdc.202000675
Kirtipal N, Bharadwaj S, Kang SG (2020). From SARS to SARSCoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses. Infection, Genetics and Evolution 85: 104502. doi: 10.1016/j.meegid.2020.104502
Miller BR, McGee TD, Swails JM, Homeyer N, Gohlke H et al. (2012). MMPBSA.py: an efficient program for end-state free energy calculations. Journal of Chemical Theory and Computation 8: 3314-3321.
Molavi Z, Razi S, Mirmotalebisohi SA, Adibi A, Sameni M et al. (2021). Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach. Biomedicine & Pharmacotherapy 138: 111544. doi: 10.1016/j.biopha.2021.111544
Potere N, Valeriani E, Candeloro M, Tana M, Porreca E et al. (2020). Acute complications and mortality in hospitalized patients with coronavirus disease 2019: a systematic review and metaanalysis. Critical Care 24 (1): 389. doi: 10.1186/s13054-020- 03022-1
Reichman RC, Morse GD, Demeter LM, Resnick L, Bassiakos Y et al. (1995). Phase I study of atevirdine, a nonnucleoside reverse transcriptase inhibitor, in combination with zidovudine for human immunodeficiency virus type 1 infection. Journal of Infectious Diseases 171 (2): 297-304.
Rothan HA, Teoh TC (2021). Cell-based high-throughput screening protocol for discovering antiviral inhibitors against SARSCOV-2 main protease (3CLpro). Molecular Biotechnology 63 (3): 240-248. doi: 10.1007/s12033-021-00299-7
Ruano‐Gallego D, García‐Villadangos M, Moreno‐Paz M, Gómez‐Elvira J, Postigo M et al. (2021). A multiplex antigen microarray for simultaneous IgG and IgM detection against SARS‐CoV‐2 reveals higher seroprevalence than reported. Microbial Biotechnology 14 (3): 1228-1236. doi: 10.1111/1751- 7915.13801
Scott LJ, Ormrod D, Goa KL (2001). Cefuroxime axetil: an updated review of its use in the management of bacterial infections. Drugs 61 (10): 1455-1500. doi: 10.2165/00003495-200161100- 00008
Shitrit A, Zaidman D, Kalid O, Bloch I, Doron D et al. (2020). Conserved interactions required for inhibition of the main protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Scientific Reports 10 (1): 20808. doi: 10.1038/ s41598-020-77794-5
Silvestrini L, Belhaj N, Comez L, Gerelli Y, Lauria A et al. (2021). The dimer-monomer equilibrium of SARS-CoV-2 main protease is affected by small molecule inhibitors. Scientific Reports 11 (1): 9283. doi: 10.1038/s41598-021-88630-9
Singh R, Gautam A, Chandel S, Sharma V, Ghosh A et al. (2021). Computational screening of FDA approved drugs of fungal origin that may interfere with SARS-CoV-2 spike protein activation, viral RNA replication, and post‐translational modification: a multiple target approach. In Silico Pharmacology 9 (1): 27. doi: 10.1007/s40203-021-00089-8
Solaimanzadeh I (2020). Nifedipine and Amlodipine Are Associated with Improved Mortality and Decreased Risk for Intubation and Mechanical Ventilation in Elderly Patients Hospitalized for COVID-19. Cureus 12 (5): e8069. doi: 10.7759/cureus.8069
Sugimoto T, Hayashi T, Okita A, Morino A (1996). Pharmacokinetics of the new thyrotropin releasing hormone analogue montirelin hydrate. 3rd communication: identification of metabolites in rat urine. Arzneimittel-forschung 46 (2): 127-133.
Tutumlu G, Dogan B, Avsar T, Orhan MD, Calis S et al. (2020). Integrating ligand and target-driven based virtual screening approaches with in vitro human cell line models and timeresolved fluorescence resonance energy transfer assay to identify novel hit compounds against BCL-2. Frontiers in Chemistry 8: 167. doi: 10.3389/fchem.2020.00167
Wu Y, Ho W, Huang Y, Jin D-Y, Li S et al. (2020). SARS-CoV-2 is an appropriate name for the new coronavirus. The Lancet 395 (10228): 949-950. doi: 10.1016/S0140-6736(20)30557-2
Yoon Y-S, Jang Y, Hoenen T, Shin H, Lee Y et al. (2020). Antiviral activity of sertindole, raloxifene and ibutamoren against transcription and replication-competent Ebola virus-like particles. Journal of Biochemistry and Molecular Biology 53 (3): 166.
Yoshino R, Yasuo N, Sekijima M (2020). Identification of key interactions between SARS-CoV-2 main protease and inhibitor drug candidates. Scientific Reports 10 (1): 12493. doi: 10.1038/ s41598-020-69337-9
Zhang L, Lin D, Sun X, Curth U, Drosten C et al. (2020). Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science 368 (6489): 409-412. doi: 10.1126/science.abb3405